Benitec Q2 net loss $6.8M; first BB-301 subject cleared DSMB review – enrollment continues

Benitec Biopharma Inc.

2024-Q2 EPS reported -$5.39

Net loss of $6.8M ($2.64 per share) for quarter ended Dec 31, 2023 vs $5.4M ($3.34) a year ago.
Cash and cash equivalents $20.4M at Dec 31, 2023, up from $2.5M at June 30, 2023.
First subject dosed with BB-301 in Nov 2023; DSMB review found no dose-limiting toxicities, recommended continuation without modifications.
23 subjects enrolled in OPMD natural history study; second subject scheduled to receive BB-301 in Feb 2024.
Interim safety and efficacy data from Phase 1b/2a Clinical Treatment Study expected mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Benitec Biopharma Inc. reported financial results for fiscal quarter ended December 31, 2023.

Period: fiscal quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 13, 2024, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2023.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-032956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.